Denali Therapeutics (DNLI) News Today $13.17 -0.10 (-0.75%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$13.06 -0.11 (-0.87%) As of 04/15/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Fmr LLC Buys 188,368 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Fmr LLC lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 2.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,019,746 shares of the company's stock after purchasing an additional 188,368 shares during the quarteApril 15 at 4:50 AM | marketbeat.comGeode Capital Management LLC Trims Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)Geode Capital Management LLC lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,935,283 shares of the company's stock afteApril 15 at 4:20 AM | marketbeat.comCantor Fitzgerald Analysts Lower Earnings Estimates for DNLIDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings estimates for Denali Therapeutics in a research report issued to clients and investors on Thursday, April 10th. Cantor Fitzgerald analyst J. Schimmer now forecasts thatApril 15 at 1:32 AM | marketbeat.comCantor Fitzgerald Analysts Cut Earnings Estimates for DNLIApril 14 at 1:33 AM | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Cantor FitzgeraldCantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday.April 12, 2025 | marketbeat.comTrexquant Investment LP Buys 36,122 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Trexquant Investment LP increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 147.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,656 shares of the company's stock after pApril 12, 2025 | marketbeat.comDenali Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldApril 10, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Reaches New 1-Year Low - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Sets New 52-Week Low - Time to Sell?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Reduces Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)ADAR1 Capital Management LLC decreased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,826 shares of the company's stApril 9, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Raymond James Financial Inc. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 26,143 shares of the company's stock, valued aApril 9, 2025 | marketbeat.com1,065,608 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Norges BankNorges Bank bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,065,608 shares of the company's stock, valued at approximately $21,717,00April 8, 2025 | marketbeat.comSchroder Investment Management Group Has $5.02 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Schroder Investment Management Group increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,800 shares of the companyApril 7, 2025 | marketbeat.comVanguard Group Inc. Increases Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)Vanguard Group Inc. grew its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 7.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,021,230 shares of the company's stock afterApril 7, 2025 | marketbeat.comCinctive Capital Management LP Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Cinctive Capital Management LP cut its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 12.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 130,445 shares of the company's stock after selling 18,649 shares duriApril 5, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Position Raised by Alliancebernstein L.P.Alliancebernstein L.P. grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 8.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,315,642 shares of the company's stock after purchasing an adApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)KLP Kapitalforvaltning AS purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 26,100 shareApril 5, 2025 | marketbeat.comDenali Initiates BLA Filing For Accelerated Approval Of Hunter Syndrome TreatmentApril 4, 2025 | nasdaq.comDenali Therapeutics (NASDAQ:DNLI) Trading 4.1% Higher - Still a Buy?Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 4.1% - Here's WhyApril 4, 2025 | marketbeat.comGroupama Asset Managment Raises Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Groupama Asset Managment raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 110,207 shares of the company's stock after acquiring an additioApril 4, 2025 | marketbeat.comWellington Management Group LLP Trims Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)Wellington Management Group LLP lessened its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,847,951 shares of the company's stock afterApril 4, 2025 | marketbeat.comAmerican Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)American Century Companies Inc. increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 480,529 shares of the comApril 4, 2025 | marketbeat.comWilliam Blair Sticks to Their Buy Rating for Denali Therapeutics (DNLI)April 3, 2025 | markets.businessinsider.comDenali initiates BLA filing for accelerated approval of tividenofusp alfaApril 2, 2025 | markets.businessinsider.comDenali Therapeutics set to advance groundbreaking treatments for neurological diseasesApril 2, 2025 | msn.comDenali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START ProgramApril 2, 2025 | globenewswire.comDenali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low - Should You Sell?Denali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month Low - Should You Sell?April 2, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 7.7% - Here's WhyDenali Therapeutics (NASDAQ:DNLI) Shares Down 7.7% - Should You Sell?April 1, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Artisan Partners Limited PartnershipArtisan Partners Limited Partnership reduced its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,054,523 shares of the company's stock after selling 36,495 sMarch 30, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Thrivent Financial for LutheransThrivent Financial for Lutherans lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 33.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 92,972 shares of the company's stock after selling 45,March 30, 2025 | marketbeat.comSegall Bryant & Hamill LLC Invests $5.89 Million in Denali Therapeutics Inc. (NASDAQ:DNLI)Segall Bryant & Hamill LLC bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 289,075 shares of the company's stock, valued at approximatelyMarch 28, 2025 | marketbeat.comDenali Therapeutics Becomes Oversold (DNLI)March 28, 2025 | nasdaq.comDenali Therapeutics (NASDAQ:DNLI) Sets New 1-Year Low - Here's WhyDenali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low - Here's What HappenedMarch 27, 2025 | marketbeat.comPier Capital LLC Acquires 164,237 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Pier Capital LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 97.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 332,319 shares of the company's stock after purchasing an additionMarch 26, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received an average rating of "Moderate Buy" from the eighteen brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommMarch 26, 2025 | marketbeat.comFox Run Management L.L.C. Makes New $788,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)Fox Run Management L.L.C. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,668 shares of the company's stock, valued atMarch 25, 2025 | marketbeat.comProficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)Proficio Capital Partners LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,210 shares of the companMarch 24, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Intech Investment Management LLCIntech Investment Management LLC boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 60.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,401 shares of the company's stock after acquiringMarch 23, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Holdings Boosted by Yiheng Capital Management L.P.Yiheng Capital Management L.P. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 16.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 700,098 shares of the company's stock after purchasinMarch 22, 2025 | marketbeat.com19,782 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Wealthfront Advisers LLCWealthfront Advisers LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,782 shares of the company's stock, valued at approximately $403,000.March 17, 2025 | marketbeat.comFY2027 Earnings Estimate for DNLI Issued By Zacks ResearchDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Zacks Research issued their FY2027 earnings per share estimates for Denali Therapeutics in a research note issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty forecasts that the company will posMarch 17, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 8.9% Following Analyst DowngradeDenali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst DowngradeMarch 11, 2025 | marketbeat.comBank of America Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $28.00Bank of America cut their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Monday.March 11, 2025 | marketbeat.comDenali Therapeutics (DNLI) Receives a Buy from Bank of America SecuritiesMarch 10, 2025 | markets.businessinsider.comBank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Bank of New York Mellon Corp decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,242,987 shares of the company's stock after selling 87,364 shares duriMarch 10, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Now Covered by Analysts at Morgan StanleyMorgan Stanley initiated coverage on Denali Therapeutics in a report on Friday. They issued an "overweight" rating and a $33.00 price target for the company.March 8, 2025 | marketbeat.comQ2 EPS Estimates for Denali Therapeutics Cut by B. RileyDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at B. Riley lowered their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the company willMarch 8, 2025 | marketbeat.comDenali Therapeutics assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comWhat is B. Riley's Estimate for DNLI FY2029 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of $0.87March 7, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Candriam S.C.A.Candriam S.C.A. cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 832,977 shares of the company's stock after selling 109,181March 7, 2025 | marketbeat.comDenali Therapeutics' (DNLI) "Buy" Rating Reaffirmed at B. RileyB. Riley restated a "buy" rating and set a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday.March 6, 2025 | marketbeat.com Remove Ads Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼0.680.79▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼146▲DNLI Articles Average Week Remove Ads Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Lantheus News Today Revolution Medicines News Today BridgeBio Pharma News Today TG Therapeutics News Today Legend Biotech News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Sarepta Therapeutics News Today Blueprint Medicines News Today Axsome Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
